Designing CAR-T cell therapy for clear cell renal cell carcinoma: preclinical evaluation using cell sorting and single cell sequencing
Presented by Select Science
Chimeric antigen receptor (CAR)-T cell therapy is a new type of “living drug” that has proven to be a powerful immunotherapy for hematologic malignancies. However, this success has not yet been transferred to solid tumors due to inefficient homing of CAR-T cells, the immunosuppressive tumor microenvironment (TME), and on-target off-tumor toxicities due to the shared epitopes on healthy tissues. The tumor associated antigen carbonic anhydrase IX (CA-IX) is overexpressed on clear cell renal cell carcinomas (ccRCC) and many other solid tumors.
Join this webinar to learn how engineered anti–CA-IX targeted CAR-T cells secreting human anti-programmed death ligand 1 (PDL-1) antibodies at the tumor site restore active anti-tumor immunity. An elevated expression of pro-inflammatory genes, downregulation of inhibitory immune modulator genes, and less regulatory T-cell differentiation of 4-1BB are observed during the CAR-T mediated response. In addition, anti–PDL-1 secreting CAR-T cells exhibit superior efficacy and less exhaustion and reverse the TME.
Learning objectives:
- Learn how engineered CAR-T cells are purified using the microfluidics chip based MA900 cell sorter for downstream functional assays.
- Review the workflow for evaluating the efficacy and long-term persistence of CAR-T cells in preclinical studies and for profiling enriched tumor infiltrating lymphocytes using single cell RNA sequencing.
- Understand how ex vivo engineered T cells represent an innovative approach to achieving a durable, long term, complete response against solid tumors.
Who should attend
This webinar will provide insights to researchers who want to learn how CAR-T cells secreting PDL-1 antibodies can be engineered for targeting solid tumors such as ccRCC.
Speaker
Yufei Wang, PhD
Postdoctoral Fellow
Dana-Farber Cancer Institute/Harvard Medical School
Dr. Yufei Wang is currently a postdoctoral fellow at Dana-Farber Cancer Institute/Harvard Medical School in the Department of Cancer Immunology and Virology under the mentorship of Dr. Wayne Marasco and Dr. Gordon Freeman. Her research focuses on the tumor microenvironment and developing CAR-T cell therapy for clear cell renal cell carcinoma. She received the 2021 Wong Family Award in Translational Oncology and the AACR-Doreen J. Putrah Cancer Research Foundation Scholar-In-Training Award. She holds a doctoral degree from Peking University in oncology and cancer biology.